The USFDA has scheduled a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Wednesday March 1, 2023. The committee will meet in open session to discuss and make recommendations on the safety and effectiveness of AREXVY (Respiratory Syncytial Virus Vaccine, Recombinant, Adjuvanted), manufactured by GSK, with a requested indication, in BLA 125775 (STN 125775/0), for active immunization for the prevention of LRTD caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older.